Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of RNA01:20

Types of RNA

Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in regulating gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA Performs Diverse...
Types of RNA01:23

Types of RNA

Overview
Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in the regulation of gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA...
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Global changes in gene expression and splicing in alcoholic liver disease.

Scientific reports·2026
Same author

Drug Development.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Experimental menopause in 3xTg-AD mice exacerbates metabolic, inflammatory, and osteologic phenotypes aligned with Alzheimer's disease pathology.

Research square·2025
Same author

A new ANMerge-based blood transcriptomic resource to support Alzheimer's disease research.

medRxiv : the preprint server for health sciences·2025
Same author

Dysregulation of Central-Medial Amygdala Histone Modifiers in Preclinical Models of Ethanol Exposure.

Addiction biology·2025
Same author

Global Changes in Gene Expression and Splicing in Alcoholic Liver Disease.

Research square·2025
Same journal

R&D productivity trends for biopharma companies in Asia and emerging markets.

Nature reviews. Drug discovery·2026
Same journal

Growth in clinical research capability in China and impact on the pharmaceutical sector.

Nature reviews. Drug discovery·2026
Same journal

Circular RNA guides exon skipping in DMD.

Nature reviews. Drug discovery·2026
Same journal

p38α inhibition restores axonal transport.

Nature reviews. Drug discovery·2026
Same journal

Inflammatory bowel disease-on-a-chip.

Nature reviews. Drug discovery·2026
Same journal

Designing GPCR-targeted miniproteins.

Nature reviews. Drug discovery·2026
See all related articles

Related Experiment Video

Updated: May 11, 2026

Overexpressing Long Noncoding RNAs Using Gene-activating CRISPR
13:04

Overexpressing Long Noncoding RNAs Using Gene-activating CRISPR

Published on: March 1, 2019

Targeting long non-coding RNA to therapeutically upregulate gene expression.

Claes Wahlestedt1

  • 1Center for Therapeutic Innovation and the Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, 1501 NW 10th Avenue, Miami 33136, Florida, USA. cwahlestedt@med.miami.edu

Nature Reviews. Drug Discovery
|June 1, 2013
PubMed
Summary
This summary is machine-generated.

Pharmaceuticals often inhibit, but activating pathways is needed. Long non-coding RNAs (lncRNAs) offer a new target, with antagoNAT oligonucleotides showing therapeutic potential by modulating gene expression.

More Related Videos

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

In Vitro Selection of Engineered Transcriptional Repressors for Targeted Epigenetic Silencing
10:44

In Vitro Selection of Engineered Transcriptional Repressors for Targeted Epigenetic Silencing

Published on: May 5, 2023

Related Experiment Videos

Last Updated: May 11, 2026

Overexpressing Long Noncoding RNAs Using Gene-activating CRISPR
13:04

Overexpressing Long Noncoding RNAs Using Gene-activating CRISPR

Published on: March 1, 2019

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

In Vitro Selection of Engineered Transcriptional Repressors for Targeted Epigenetic Silencing
10:44

In Vitro Selection of Engineered Transcriptional Repressors for Targeted Epigenetic Silencing

Published on: May 5, 2023

Area of Science:

  • Molecular Biology
  • Genetics
  • Pharmacology

Background:

  • Current drugs primarily inhibit biological processes, creating a need for agents that can enhance pathway activity.
  • Upregulating specific genes, such as tumor suppressors or those deficient in genetic disorders, holds therapeutic promise.
  • Regulatory long non-coding RNAs (lncRNAs) are emerging as critical regulators of gene expression and chromatin structure.

Purpose of the Study:

  • To review the mechanisms by which lncRNAs regulate gene expression.
  • To explore the role of lncRNAs in various diseases.
  • To discuss the development and therapeutic potential of antagoNAT oligonucleotides targeting natural antisense transcripts (NATs).

Main Methods:

  • Literature review of lncRNA mechanisms and roles in disease.
  • Focus on antagoNAT oligonucleotides as inhibitors of NAT lncRNAs.
  • Analysis of challenges in therapeutic applications of antagoNATs.

Main Results:

  • lncRNAs can both activate and repress gene expression and influence chromatin architecture.
  • NATs represent a class of lncRNAs amenable to inhibition by oligonucleotide-based therapeutics.
  • The design and application of antagoNAT oligonucleotides are advancing.

Conclusions:

  • lncRNAs are versatile regulators with significant implications for disease.
  • AntagoNAT oligonucleotides offer a novel strategy for therapeutic intervention by targeting lncRNAs.
  • Further research is needed to address challenges for the clinical translation of antagoNAT-based therapies.